SPR Therapeutics Wins Nod for Dual Lead PNS System

The use of neurostimulation could be an effective weapon in the long fight to eliminate the opioid epidemic in the U.S. FDA just recently signed off on a neurostimulation pain treatment therapy from SPR Therapeutics. The Cleveland-based company said it has received clearance to market the Sprint extensa (dual lead) Peripheral Nerve Stimulation (PNS) System. The company also received clearance for some updated features on its single lead pain treatment application. “This recent clearance allows now for a dual lead or two lead to be used in the treatment of pain and it allows us to target just more than one nerve,” Maria Bennett, SPR Therapeutics Founder, President and CEO, told MD+DI. “There are some types of pain that require two different nerves to be targeted in order to provide maximum or optimal pain relief.” SPR Therapeutics said the Sprint PNS System is the only percutaneous device that is FDA-cleared for both chronic and acute pain, including post-operative and post-traumatic pain. The Sprint PNS System leads are placed by a physician during an outpatient procedure without surgery, incisions, tissue destruction or anesthesia offering a minimally invasive and non-opioid 60-day therapy. The company had originally received FDA clearance for the Sprint PNS System in 2016. The current nod from FDA comes around the same time the agency awarded a contract to the National Academies of Sciences, Engineering...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news